Published in:
01-03-2015 | Urology - Original Paper
Does metabolic syndrome increase the risk of infective complications after prostate biopsy? A critical evaluation
Published in: International Urology and Nephrology | Issue 3/2015
Login to get accessAbstract
Purpose
To evaluate the possible association between metabolic syndrome (MetS) and infectious complications after prostate biopsy.
Methods
A total of 480 men underwent prostatic biopsy due to elevated prostate-specific antigen levels and/or abnormal digital rectal examination. Patients were divided into two subgroups with respect to the presence or absence of MetS. Patients in both groups were closely followed with respect to infectious complications after biopsy and the possible effect of MetS as a certain risk factor on these complications was evaluated with a multivariate analysis.
Results
Infectious complications were observed in 33 cases (6.8 %), while urinary tract infection (UTI) was detected in 30 (6.2 %) cases, sepsis occurred in three (0.6 %) cases. The percentage of the cases with infectious complications was 11.0 and 3.4 % in men with and without MetS, respectively (p = 0.002). These rates were 3.7 versus 1.5 %, respectively, for UTI (p < 0.003) and 0.9 versus 0.4 %, respectively, for sepsis in both groups (p = 0.594). Multivariate analysis of the data confirmed that MetS was associated with an increased risk of infective complications (odds ratio 3.44 and 95 % CI 1.56–7.58, p < 0.002) after this procedure.
Conclusions
MetS could pose a certain increased risk for infectious complications after prostate biopsy. Patients with MetS should be considered as risk cases for this procedure, and they should be evaluated and followed in a very close manner with respect to these complications.